Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Erlotinib (Tarceva) Given Intermittently During First Line Standard Platinum Containing Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00448240 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.

NCT NCT00448240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00448240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Erlotinib (Tarceva) Given Intermittently During First Line Standard Platinum Containing Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Henry Ford Health System
Phase
Phase 2/3
Overall status
Terminated
Start date
February 28, 2007
Completion date
January 31, 2012
Enrollment
6 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell, head and neck cancer